Abstract

In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).

Keywords

SemaglutideAgonistGlucagon-like peptide 1 receptorType 2 diabetesMedicineReceptorInternal medicineEndocrinologyDiabetes mellitusGlucagon-like peptide-1Liraglutide

MeSH Terms

Blood GlucoseDiabetes MellitusType 2Dose-Response RelationshipDrugDrug Administration ScheduleDrug TherapyCombinationFemaleGastric Inhibitory PolypeptideGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsIncretinsInjectionsSubcutaneousMaleMetforminMiddle AgedNauseaWeight LossTirzepatideGlucagon-Like Peptide-1 Receptor Agonists

Affiliated Institutions

Related Publications

Publication Info

Year
2021
Type
article
Volume
385
Issue
6
Pages
503-515
Citations
1528
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1528
OpenAlex
88
Influential
1440
CrossRef

Cite This

Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine , 385 (6) , 503-515. https://doi.org/10.1056/nejmoa2107519

Identifiers

DOI
10.1056/nejmoa2107519
PMID
34170647

Data Quality

Data completeness: 90%